Skip to main content Accessibility help

The prevalence of neuroleptic malignant syndrome in learning disability

  • Caryl N Morgan (a1) and Renarta Rowe (a2)


Objectives: No information has been published on the incidence of neuroleptic malignant syndrome in learning disability. However, some studies of individuals who have developed neuroleptic malignant syndrome have suggested that individuals with learning disabilities may be over represented. This study aims to identify the association between learning disability and neuroleptic malignant syndrome.

Method: A retrospective case-note analysis was performed with psychiatric case notes for clients with learning disability, in two geographical catchment areas. It was recorded whether clients had been exposed to neuroleptics, and whether any neurological symptoms had subsequently developed which could have been suggestive of neuroleptic malignant syndrome.

Results: It was found that 301 individuals had been exposed to neuroleptics, out of 570 case notes examined. Only one case of neuroleptic malignant syndrome was identified, giving a lifetime prevalence rate of 0.3%.

Conclusion: This study failed to demonstrate a higher than expected prevalence of neuroleptic malignant syndrome in clients with learning disability exposed to neuroleptics.



Hide All
1.Jahan, MS, Farooque, AI, Wahid, Z. Neuroleptic malignant syndrome. JAMA. 1992; 84(11): 966970.
2.Kohen, D, Bristow, M. Neuroleptic malignant syndrome. Advances in Psychiatric Treatment. 1996; 2: 151157
3.Fitzgerald, B, Middleton, JK, Cooper, SA. Adverse effects of summer amongst people with learning disability: A case report. J Intellect Disabil. 1997; 42(3): 273277.
4.Addonizio, G, Susman, VL, Roth, SD. Neuroleptic malignant syndrome: review and analysis of 115 cases. Biol Psychiat 1987; 22: 10041020.
5.Pearlman, CA. Neuroleptic malignant syndrome. A review of the literature. J Clin Psychopharm. 1986; 6: 257273.
6.Clarke, DJ, Kelly, S, Thinn, K, Corbett, JA. Psychotropic drugs and mental retardation. 1. Disabilities and the prescription of drugs for behaviour and for epilepsy in three residential settings. J Ment Def Res. 1990 Oct; 34 (5): 385395.
7.Robertson, J, Emerson, E, Gregory, N, Hatton, C, Kessissoglou, S, Hallam, A. Receipt of psychotropic medication by people with intellectual disability in residential settings. B J Intellect Dis. 2000 Oct; 44 (6): 666676.
8.Levenson, JL. Neuroleptic malignant syndrome. Am J of psychiatry. 1985; 142: 11371145.
9.Rosebush, P. Stewart, T. A prospective analysis of 24 episodes of neuroleptic malignant syndrome. Am J Psychiatry. 1989; 146: 717725.
10.Adityanjee, , Aderibigbe, YA, Matthews, T. Epidemiology of neuroleptic malignant syndrome. Clin Neuropharmacol 1999; 22(3): 151158.
11.DSM IV. American Psychiatric Association. 1994.



Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed